Summary The National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium
(CPTAC) investigates tumors from a proteogenomic perspective, creating rich multi-omics …

Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Mass-spectrometry-based proteomic data on human tumors—combined with corresponding
multi-omics data—present opportunities for systematic and pan-cancer proteogenomic …

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few
therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a …

Abstract Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-
negative (HER2−) breast cancer is the most prevalent type of breast cancer, in which …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug
Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) …

Chromatin accessibility is essential in regulating gene expression and cellular identity, and
alterations in accessibility have been implicated in driving cancer initiation, progression and …

Activated T cells secrete interferon-γ, which triggers intracellular tryptophan shortage by
upregulating the indoleamine 2, 3-dioxygenase 1 (IDO1) enzyme,,–. Here we show that …